[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Crinetics Pharmaceuticals insider sale by President & CEO Richard S. Struthers. The filing reports that on 09/26/2025 Mr. Struthers sold 4,000 shares of common stock in open-market transactions at $45.00 per share under a Rule 10b5-1 trading plan adopted August 30, 2024. The Form 4 lists his post-transaction beneficial holdings across direct and indirect holdings, including 320,017 shares held directly and multiple indirect holdings via family trusts and spouse (for example, 661,205 shares by Family Trust 1 and 106,000 shares indirect by Family Trust 2). The sale was effected automatically under the trading plan and was signed by an attorney-in-fact on 09/30/2025.

Positive

• Sale executed under a Rule 10b5-1 trading plan, indicating the trade was pre-planned and automated
• Detailed disclosure of post-transaction beneficial ownership including direct and indirect holdings by multiple family trusts and spouse

Negative

• None.

Insights

Securities Analyst

Insider sold a small number of shares under a pre-established plan; holdings remain substantial.

The reported sale of 4,000 shares at $45 each appears to be a routine disposition executed under a Rule 10b5-1 plan, which typically indicates pre-planned liquidity rather than opportunistic trading. The filing shows significant remaining beneficial ownership reported both directly and indirectly across several family trusts and spouse, which suggests continued alignment of the reporting person with long-term ownership. No derivative transactions or additional dispositions are disclosed in this form.

Corporate Governance Expert

Transaction follows governance best practices using a 10b5-1 plan; disclosure is complete for the reported trade.

The Form 4 cites adoption of a Rule 10b5-1 trading plan on August 30, 2024 and describes an automatic sale executed on 09/26/2025. The filing identifies the reporting person as both President & CEO and a director and provides post-transaction beneficial ownership broken out by direct and indirect holdings. The signature by attorney-in-fact is properly recorded. There are no indications of other compensatory or derivative grants in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Struthers Richard Scott

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/26/2025		S(1)		4,000	D	$45(2)	106,000	I	By Family Trust 2
Common Stock								320,017	D
Common Stock								661,205	I	By Family Trust 1
Common Stock								110,000	I	By Family Trust 3
Common Stock								100,000	I	By Family Trust 4
Common Stock								1,000	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $45.00 per share.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	09/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Richard S. Struthers disclose in the Form 4 for CRNX?

The Form 4 reports that Richard S. Struthers sold 4,000 shares of Crinetics common stock on 09/26/2025 at a price of $45.00 per share under a Rule 10b5-1 plan.

Was the insider sale part of a Rule 10b5-1 trading plan for CRNX?

Yes. The filing states the sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2024.

How much CRNX stock does the reporting person beneficially own after the transaction?

The Form 4 lists multiple holdings after the sale, including 320,017 shares directly and indirect holdings such as 661,205 shares by Family Trust 1 and 106,000 shares by Family Trust 2, among others.

Did the Form 4 report any derivative transactions for CRNX?

No. Table II for derivative securities shows no entries; only a non-derivative common stock sale is reported.

Who signed the Form 4 for the reporting person?

The Form 4 was signed by Tobin Schilke, as attorney-in-fact on 09/30/2025.